Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T17:37:36.282Z.
Consensus retrieved: 2026-10-06T14:52:38.548Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T17:37:36.282Z.
Quote observation: 2026-10-06T17:35:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0b6e81bfb968b053e3c664bae947515aab5c23e1d2a9854177de48c3869b2902
Forward PE Ratio (N/A) = Dated Quote Price ($78.94) / Consensus Forward EPS ($-2.40)
FORWARD PE RATIO
N/A
Oruka Therapeutics, Inc.
Market Cap
$4.76B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | $4.76B | N/A |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.79B | N/A |
| LifeStance Health Group, Inc. (LFST)vs › | $4.68B | 75.22 |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.67B | N/A |
| BillionToOne, Inc. (BLLN)vs › | $4.66B | 127.62 |
| Option Care Health, Inc. (OPCH)vs › | $4.66B | 16.54 |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.65B | N/A |
| Erasca, Inc. (ERAS)vs › | $4.97B | N/A |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.05B | N/A |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.06B | 19.70 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $78.94, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.40 | $-2.63 – $-2.19 | 7 | n/m |
| 2027-12-31 | $-2.83 | $-3.38 – $-2.16 | 7 | n/m |
| 2028-12-31 | $-3.62 | $-6.08 – $-2.65 | 7 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
